Update in the Management of Penile Cancer

Jorge R. Caso, Alejandro R. Rodriguez, Jose Correa, Philippe E. Spiess

Division of Genitourinary Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

ABSTRACT

Purpose: The management of penile cancer has evolved as less invasive techniques are applied in the treatment of the primary tumor and inguinal lymph nodes.

Materials and Methods: Herein we review the literature focusing on advances in the preservation of the phallus as well as less morbid procedures to evaluate and treat the groins.

Results: Promising imaging modalities for staging are discussed. New techniques are described and tables provided for penile preservation. We also review the contemporary morbidity of modified surgical forms for evaluation of the inguinal nodes.

Conclusions: Advances in surgical technique have made phallic preservation possible in a greater number of primary penile cancers. The groins can be evaluated for metastasis with greater accuracy through new radiologic means as well as with less morbid modified surgical techniques.

Key words: penile cancer; staging; treatment; lymphadenectomy


INTRODUCTION

In the United States squamous cell carcinoma of the penis is a rarely diagnosed malignancy with an incidence of 0.58 cases per 100,000 (1). This rate has been in gradual decline over the last thirty years (1). In developing countries, the incidence is more considerable, due in part to cultural and hygienic differences (2,3). Several etiologic risk factors have been recognized in the development of this malignancy. Exposure to the human papillomavirus, lack of neonatal circumcision (especially when associated with phimosis), and exposure to tobacco, among other causes, have been implicated (2-5).

In this article, we review the current management of penile carcinoma. An overview of newer phallic preservation techniques, as well as the staging of the inguinal nodes with minimally invasive and non-invasive methods, will be provided.

STAGING

Staging is usually accomplished via the 1987 TNM classification, most recently released in 2002 (6). It has been criticized for prognostic inadequacies as well as for the difficulty of properly assessing clinical stage using only the physical exam and imaging (7). Indeed, some authors choose to report contemporary series according to the 1978 classification (8,9), due in part to a belief that therapy should be determined only by the prior assignment of a clinical stage (10,11).
With regards to the primary tumor, the initial assessment should be made by physical examination. It has been shown that in experienced hands, its correlation with the histopathologic examination after surgery is superior to that which can be derived from magnetic resonance imaging (MRI) or ultrasound (US) (12). These modalities would be reserved for lesions in which an adequate exam could not be performed, such as in the morbidly obese patient. However, the use of an intracavernosal injection of prostaglandin E1 as an adjunct prior to MRI scan has shown promise in some series by improving its accuracy in assessing the clinical stage of the primary tumor (13,14). The sensitivities and specificities, respectively, for this modality in correctly assessing clinical T1 tumors are 85% and 83%, for T2 tumors 75% and 89%, and for T3 tumors 88% and 98% (14). Additionally, a biopsy of the lesion is necessary to confirm the diagnosis. The clinician must be wary, however, as prognostic pathological clues are not always apparent on superficial biopsy, and the grade and stage may differ from that of the final specimen (15). This latter point is especially important as penile conservation therapies become increasingly promoted, thereby eliminating the chance for more complete pathologic review from an amputation specimen.

Equally problematic is the staging of nodal disease. Here again, the initial assessment is made by physical examination, through palpation of the bilateral inguinal region. If the nodes are non-palpable after an adequate physical exam, there is generally no indication for imaging (16). However, new technologies such as lymphotropic nanoparticle enhanced MRI may enhance or replace the palpated findings. In a series of seven patients a total of 113 lymph nodes were evaluated and 13 found to be malignant on node dissection. The calculated sensitivity was 100% and negative predictive value also 100% (17). A specificity of 97% and positive predictive value of 81% was attributed to false positives secondary to fibrotic nodes (17). This technique not only indicated for which patients should undergo lymphadenectomy, but also specified laterality. High-resolution transducer US, which relies on several morphologic characteristics of malignant nodes (such as shape, echogenicity, and internal structures, among others) may also have a role in identifying patients with metastases (18). These methods should be differentiated from traditional computed axial tomography (CT), MRI, and US imaging, which use size criteria to identify suspicious nodes and are therefore associated with a higher rate of false positives.

When the nodes are palpable, management usually consists of 4-6 weeks of antibiotics commencing after the primary lesion has been treated (19). Almost half of suspicious lymph nodes palpated during the initial presentation are enlarged due to inflammatory changes; however, those that become palpable during later surveillance are malignant in 70 to 100% of cases (16,20). If the inguinal lymph nodes are positive for cancer, evaluation of the pelvic nodes should be carried out with a CT (16) or MRI. The imaging field may be extended to the abdomen if disease is present in the pelvis, and all patients with node positive disease should also undergo a chest X-ray (16). A chest X-ray may also be considered in all newly diagnosed patients, with chest CT follow-up for suspicious findings. Although not standard, positron emission tomography alone or in conjunction with CT has shown promise in detecting metastatic lesions (21,22). In one study of thirteen patients, five of whom had histopathologically proven lymph node metastasis, 15 of 16 lymph nodes were identified as true positives, while 1 of 9 lymph nodes was a false negative (22).

SURGERY OF THE PRIMARY TUMOR

The obvious psychological toll associated with genital disfigurement has prompted the development of organ sparing techniques. Carcinoma in situ has been successfully treated with photodynamic therapy (PDT) and topical agents. In the largest reported series of PDT ten patients-three of which had Bowenoid papulosis- received therapy with an average of 4.5 treatments in those who were completely cleared (23). 5-fluorouracil and more recently the immune response modifier imiquimod 5% cream have been used with biopsy proven eradication of the lesion (24-26). Cryosurgery with liquid nitrogen has been reported in superficial, low grade tumors (27).

Mohs microsurgery has had good results in tumors that are not excessively large, deeply invasive,
or involving the urethral meatus (28). Radiation, both by brachytherapy and external beam radiotherapy, preserves function and establishes cancer control in select patients (29-31). Phallic preservation is possible in over half to three-quarters of those treated in this manner. It is likely best utilized in tumors smaller than 4 cm with less than 1 cm of invasion (29). Neodymium: yttrium-aluminum-garnet (Nd: Yag) and CO2 lasers have been used primarily in early stage penile cancers, and may be particularly effective for carcinoma in situ or for T1 and T2 lesions that are 3 cm or smaller (8,32-34). Some no longer apply this technology to T2 tumors as there may be a higher risk for nodal metastasis (35). Neoadjuvant reductive chemotherapy using vincristine, bleomycin and methotrexate with peniscopy in concert with CO2 laser has been reported with favorable results (36).

In a recent large, retrospective multi-institutional series laser therapy, local excision, and radiotherapy were compared to partial or total penectomy. Local recurrence rates were higher with penile preservation compared to partial or total amputation (27.7% versus 5.3%) (34). Five year disease specific survival in those who locally recurred was 92%, however, prompting the authors to conclude that there is little impact on survival from utilizing phallic preservation techniques (34).

Modified surgical methods that avoid total or traditional partial penile amputations and remove minimal tissue are also being employed for select tumors. Glans resurfacing has been performed for carcinoma in situ and involves removing all superficial glans and coronal tissue down to the corpus spongiosum. A partial thickness skin graft is then harvested to cover the defect (37,38). “Conservative surgical techniques” consisting of completely removing a tumor guided by preoperative mapping and with frozen section examination of margins preserve uninvolved structures (39). With extended follow-up, the results have been promising (39). Glansectomy has been reported with no local recurrences in select cases (38,40,41). Others have performed partial glansectomy and partial penectomy with reconstruction of the glans (38,41,42). For results of select studies, please see Table-1.

For grade 3 and deeply invasive tumors, particularly those not on the prepuce or glans, partial or total penectomy is the standard therapy (16). Classic teaching holds that the primary penile tumor should be excised with a 2 cm margin (19); however, this has more recently been called into question. In a prospective study grade 1 and 2 tumors were found histologically to extend less than 1 cm and grade 3 tumors less than 1.5 cm from the gross margin (43). It would therefore appear that the limits of resection should be based on the grade of the tumor as determined on biopsy. This has implications for conservative surgery, and indeed in one study where organ sparing techniques were used histopathologic margins were within 1 cm in about half and less than 2 cm in 90% of the resection specimens (44). In light of these findings, some authors have advocated removing a 1 cm margin from the “palpable” (as opposed to the visible) edge of the tumor (45). Only one patient out of thirty-nine experienced a recurrence using this limit (45).

Partial penectomies should leave a 2.5-3 cm penile stump for minimal functionality (19). Large or advanced stage lesions, particularly those at the base of the penis, may be best treated by total penectomy with perineal urethrostomy (19).

**ASSESSMENT OF THE INGUINAL NODES**

Close to 25% of patients with non-palpable lymph nodes on presentation harbor metastatic disease (46). The staging modalities previously mentioned offer hope that this subgroup may be identified in a non-invasive manner in the near future. Identifying patients with occult metastases is important because it has been shown that immediate lymphadenectomy confers a survival advantage over surgery deferred until palpable disease develops (47,48). In a recent series of forty patients, the 3-year disease-specific survival of patients with metastatic nodes detected on surveillance was 35% versus 84% in those who underwent early resection (48). These numbers are very similar to those that have been reported with more extensive (6-7 year) follow-up (47).

Several risk factors for nodal metastases have been identified, and may be used to direct surgical intercession. A direct correlation between tumor grade and the likelihood of the inguinal metastases was first
established (49). In one study in which prophylactic lymphadenectomies were performed, clinically negative groins with grade 1 or 2 tumors with no or minimal invasion were cancer free whereas tumors, which invaded the corpora or were poorly differentiated had microscopic cancer in 78% of the removed lymph nodes (50). In a subsequent study tumor stage, vascular invasion, and a proportion of greater than 50% poorly differentiated cancer were shown to be independent prognostic factors for lymph node metastasis (46). More recently a nomogram has been developed which incorporates stage, grade, tumor thickness, histologic growth pattern, vascular/lymphatic embolization, and clinical node status in order to calculate the probability of the inguinal area being pathologically positive (51).

---

**Table 1 – Results of select contemporary penis conservation therapies.**

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th># Pts</th>
<th>Stage</th>
<th>Technique</th>
<th>Local Recurrence</th>
<th>Follow-up in Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Van Bezooijen (32)</td>
<td>2001</td>
<td>19</td>
<td>Tis</td>
<td>Laser (Nd:YAG, CO2)</td>
<td>26%</td>
<td>Mn 32 (1-95)</td>
</tr>
<tr>
<td>Windhal (33)</td>
<td>2003</td>
<td>67</td>
<td>Tis-T2</td>
<td>Laser (Nd:YAG, CO2)</td>
<td>19%</td>
<td>Md 42 (12-186)</td>
</tr>
<tr>
<td>Lont (8)</td>
<td>2005</td>
<td>104</td>
<td>T1, T2</td>
<td>Excision, Laser (Nd:YAG, CO2)</td>
<td>37.50%</td>
<td>Md 106 (16-543)</td>
</tr>
<tr>
<td>Meijer (35)</td>
<td>2007</td>
<td>44</td>
<td>Tis-T2</td>
<td>Excision, Laser (Nd:YAG)</td>
<td>48%</td>
<td>Mn 53.2 (+/- 43.3)</td>
</tr>
<tr>
<td>Bandieramonte (36)</td>
<td>2008</td>
<td>224</td>
<td>Tis-T1</td>
<td>Excision, Laser (CO2), Chemotherapy</td>
<td>17.5%</td>
<td>Md 66 (35-132)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leijte (34)</td>
<td>2008</td>
<td>105</td>
<td>Tis-T2</td>
<td>Local excision</td>
<td>27.7%</td>
<td>Md 60.6 (3-358)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Radiation therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>External RT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ozsahin (31)</td>
<td>2006</td>
<td>7</td>
<td>T1-T3</td>
<td>External RT, brachytherapy</td>
<td>61%</td>
<td>Md 62 (6-454)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Brachytherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minstry (30)</td>
<td>2007</td>
<td>17</td>
<td>TX, Tis-T3</td>
<td>External RT, brachytherapy</td>
<td>37%</td>
<td>NA</td>
</tr>
<tr>
<td>Crook (29)</td>
<td>2008</td>
<td>67</td>
<td>TX, Tis-T3</td>
<td>Brachytherapy</td>
<td>13%</td>
<td>Md 48 (4-194)</td>
</tr>
<tr>
<td>Shindel (28)</td>
<td>2007</td>
<td>33</td>
<td>Tis-T3</td>
<td>Mohs micrographic surgery</td>
<td>32%</td>
<td>Md 37 (0.5-214)</td>
</tr>
<tr>
<td>Bissada (39)</td>
<td>2003</td>
<td>30</td>
<td>NS</td>
<td>Conservative surgical excision</td>
<td>8%</td>
<td>12-360</td>
</tr>
<tr>
<td>Pietrzak (41)</td>
<td>2004</td>
<td>39</td>
<td>Ta-T3</td>
<td>Partial GS up to partial penectomy</td>
<td>3%</td>
<td>Mn 16</td>
</tr>
<tr>
<td>Mc Dougual (42)</td>
<td>2005</td>
<td>5</td>
<td>T1, T2</td>
<td>Partial GS</td>
<td>13%</td>
<td>12-60</td>
</tr>
<tr>
<td>Hadway (37)</td>
<td>2006</td>
<td>8</td>
<td>Tis</td>
<td>Excision of shaft skin</td>
<td>0%</td>
<td>Md 30 (7-45)</td>
</tr>
<tr>
<td>Palminteri (38)</td>
<td>2007</td>
<td>11</td>
<td>T1, T2</td>
<td>GS up to partial penectomy</td>
<td>0%</td>
<td>Mn 32 (12-60)</td>
</tr>
</tbody>
</table>

# = number; Pts = patients; NA = not available; RT = radiation therapy; GS = glansectomy; Mn = mean; Md = median
1 includes patients treated by other means; 2 interquartile range; 3 includes 4 patients who had excisional biopsy but refused definitive radiotherapy.
A less morbid approach to early, complete inguinal lymphadenectomy involves staging the groins by first sampling the sentinel lymph node or nodes. This was first performed in a static, anatomical fashion with favorable results (52) which were unfortunately not duplicated in later series (53). The technique is no longer recommended (16,53). Instead dynamic sentinel node biopsy (DSNB) has been adopted. Although there is variability between surgical groups in the exact technique, usually some time prior to the scheduled surgery a radiotracer is injected into the remnant portion of the penis closest to where the primary tumor had been resected. On the day of surgery, dye may also be injected. The sentinel lymph node(s) is thus located visually and with a probe. This has been accomplished via an open technique through skin flaps (54) or by first marking the overlying skin after detection of radioactivity (55-57). A criticism of DSNB is that the false negative rate is a relatively high 15-16% (56,58) with a consequently low sensitivity that has deemed the technique insufficient by some researchers (54). This remains true in cases where the nodes are palpable (59).

Alternatively high resolution US with fine needle aspiration of suspicious nodes may be used to identify occult metastasis and those patients who require complete lymphadenectomy. Criteria for suspicious nodes include a length to width ratio less than 2, a concentrically or eccentrically wide cortex, and a narrow to absent hilum (60). Compared to DSNB, at median follow-up of 18 months the sensitivity per groin was only 39% with a specificity of 100% (60). The authors concluded that the technique is useful in screening patients and avoiding DSNB when the aspirate is positive for cancer (60). These two modalities were used in a complementary fashion in a more recent paper. Sonographic criteria included increased size, abnormal shape, absence of echogenicity in the hilum, hypoechohogenicity of the node, necrosis, and abnormal vascularity (57). At a median follow-up of 11 months the respective sensitivity and specificity for US compared to DSNB were 74 and 77%; interestingly, US identified two patients with metastasis who were originally considered negative by DSNB (57).

Modification of the traditional inguinal lymph node dissection, popularized through the work of Catalona, is used to decrease the morbidity of inguinal lymphadenectomy (61,62). If cancer cells are found, a full template dissection is completed. Catalona’s modified boundary preserves the saphenous vein as well as the subcutaneous tissue superficial to Scarpa’s fascia; in addition fewer nodes are removed and the incision is shorter (62). The surgical boundaries are the external oblique aponeurosis and spermatic cord (superior), the fascia lata distal to the fossa ovalis (inferior), the adductor longus (medial) and the femoral artery (lateral) (62). A locoregional recurrence rate of 15% (2/13 patients) was reported in a prospective study utilizing this template (63), similar to a more recent retrospective study where one out of eleven patients (9%) had an out of field recurrence at the base of the penis (64). Slightly different boundaries were proposed by Costa et al. setting the limits at the adductor longus (medial), the medial surface of the femoral and saphenous veins (lateral), and the inguinal arcade (superior), forming a triangle (65,66). With a mean follow-up greater than six years the reported loco-regional recurrence rate was 5.5% of negative groins (or 2 out of 18, or 11% of patients) (65). The possibility of leaving disease behind has dampened enthusiasm for the modified procedures. An interesting study has recently been reported whereby hybrid single-photon emission CT lymphatic drainage patterns were analyzed in a cohort of patients. In 10%, the sentinel nodes were located in the lateral superior zone (based on Daseler’s classification) which is not sampled with either modified dissection, providing a rationale for recurrences (67).

Removing all superficial inguinal lymph node tissue for diagnosis provides a more complete assessment for staging, but has traditionally been associated with high morbidity (68,69). However, certain modifications have been introduced to lessen the chances of a severe complication. Many of the issues that arise are wound related complications; the use of a Gibson incision has been advocated by some authors to reduce them (10). Minimally invasive means of performing inguinal lymphadenectomy, via straight laparoscopy or with robotic assistance, have practically eliminated cutaneous complications (70-74). Prophylactic antibiotics, the appropriate use of drains, early ambulation, and modifications in surgical technique, among others, encompass some of the changes that have been applied with success in minimizing morbidity (68,69).
Table 2 – Complication rates in select contemporary inguinal lymphadenectomies.

<table>
<thead>
<tr>
<th>Year</th>
<th>Approach</th>
<th>Type of Surgery</th>
<th># ILND</th>
<th>Overall Complication Rate (%)</th>
<th>Leg edema (%)</th>
<th>Wound Breakdown (%)</th>
<th>Infection (%)</th>
<th>Lymphocele (%)</th>
<th>Follow up in Months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bevan-Thomas (69)</td>
<td>2002</td>
<td>Varied ⁶</td>
<td>Prophylactic</td>
<td>66</td>
<td>35</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Therapeutic</td>
<td>28</td>
<td>36</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Palliative</td>
<td>12</td>
<td>67</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Prophylactic</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Therapeutic</td>
<td>25</td>
<td>45</td>
<td>5</td>
<td>15</td>
<td>-</td>
<td>7.5</td>
</tr>
<tr>
<td>Nelson (75)</td>
<td>2004</td>
<td>Standard</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Prophylactic</td>
<td>52</td>
<td>48</td>
<td>52</td>
<td>12</td>
<td>12</td>
<td>15</td>
</tr>
<tr>
<td>Spiess (68) ⁷</td>
<td>2008</td>
<td>Superficial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Prophylactic</td>
<td>22</td>
<td>36</td>
<td>27</td>
<td>5</td>
<td>5</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MILND</td>
<td>Prophylactic</td>
<td>42</td>
<td>36.8</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Milathianakis (76)</td>
<td>2005</td>
<td>MILND</td>
<td>Diagnostic</td>
<td>10</td>
<td>87.5</td>
<td>37.5</td>
<td>-</td>
<td>37.5</td>
<td>37.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Standard</td>
<td>Diagnostic/therapeutic</td>
<td>14</td>
<td>-</td>
<td>43</td>
<td>-</td>
<td>-</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MILND</td>
<td>Diagnostic</td>
<td>14</td>
<td>-</td>
<td>43</td>
<td>-</td>
<td>-</td>
<td>7</td>
</tr>
<tr>
<td>Horenblas (55) ⁷</td>
<td>2000</td>
<td>DSLNB</td>
<td>Diagnostic</td>
<td>107</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Kroon (56)</td>
<td>2005</td>
<td>DSLNB</td>
<td>Diagnostic</td>
<td>189</td>
<td>7</td>
<td>1</td>
<td>-</td>
<td>1 necrosis</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Standard</td>
<td>Diagnostic/therapeutic</td>
<td>34</td>
<td>68</td>
<td>29</td>
<td>3</td>
<td>15 necrosis</td>
<td>12 dehiscence</td>
</tr>
<tr>
<td></td>
<td>Endoscopic</td>
<td>Endoscopic</td>
<td>Diagnostic</td>
<td>10</td>
<td>20</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tobias-Machado (71)</td>
<td>2007</td>
<td>Standard</td>
<td>Diagnostic</td>
<td>10</td>
<td>70</td>
<td>10</td>
<td>30</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Sotelo (72)</td>
<td>2007</td>
<td>Endoscopic</td>
<td>Diagnostic</td>
<td>14</td>
<td>21</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Where columns have been split, number on left indicates minor complications and on right major complications or those considered severe or those requiring surgical intervention.

All calculated percentages rounded to the closest whole number. # = number; NA = not available; ILND = inguinal lymph node dissections (M = modified, C = complete); DSLNB = dynamic sentinel lymph node biopsy; Mn = mean; Md = median. 1 variation according to intent; for prophylactic dissection modified template used, for therapeutic standard template, for palliative all fixed tissue was removed. ⁷ complications from total number of patients (not groin dissections).
For a review of complication rates for recent series of modified, standard, and endoscopic inguinal lymph node dissections, please refer to Table-2.

CONCLUSIONS

Penile cancer is a rare disease, which has been studied through relatively small case series from large academic centers. Recently, several paradigms have been altered in the management of this cancer. The drive for decreased morbidity with continued cancer control has lead to penile preservation surgery, better staging modalities, and minimally invasive techniques for the exploration of the inguinal nodes. It is hoped these techniques prove to have equivalent or better oncologic outcomes in order to lessen the morbidity associated with the surgical therapy of this disease.

CONFLICT OF INTEREST

None declared.

REFERENCES


Correspondence address:
Dr. Philippe E. Spiess
Genitourinary Oncology Program
H. Lee Moffitt Cancer Center & Research Institute
12902 Magnolia Drive
Tampa, Florida, 33612-9416, USA
Fax: + 1 813 745-8494
E-mail: philippe.spiess@moffitt.org

Accepted after revision:
February 9, 2009